nach oben

Zeitschrift für Rheumatologie

Erschienen in:

01.09.2012 | Originalien

Systematische Literaturrecherche für die S1-Leitlinie zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis

verfasst von: Dr. K. Albrecht, K. Krüger, U. Müller-Ladner, J. Wollenhaupt

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Ausgangspunkt der neuen S1-Leitlinie waren die 2010 erschienenen EULAR Recommendations zum Management der rheumatoiden Arthritis (RA), die nach umfangreichen systematischen Literaturrecherchen (SLR) evidenzbasiert erstellt worden sind. Die SLR wurde für die deutschen Empfehlungen aktualisiert und wird in ihrer Methodik vorgestellt.

Methodik

Die SLR wurde für den Zeitraum von Januar 2009 bis Ende August 2011 durchgeführt. Es wurden alle kontrollierten Studien eingeschlossen, die die krankheitsmodifizierende Therapie der RA hinsichtlich ihrer Wirksamkeit auf Klinik, Funktion und Struktur untersucht haben.

Ergebnisse

Von 6869 gesichteten Arbeiten wurden 138 Artikel und 56 Abstracts für die Erstellung der Leitlinie berücksichtigt. Auf einem Konsensustreffen wurden die Ergebnisse der SLR vorgestellt. Auf dieser Grundlage formulierte das Expertengremium modifizierte Empfehlungen und verabschiedete diese mittels Konsensus.

Schlussfolgerungen

Mithilfe der aktualisierten SLR konnten wesentliche neue Daten im Entscheidungsprozess für die neue S1-Leitlinie zur medikamentösen Therapie der RA berücksichtigt werden.

Askling J, Vollenhoven RF van, Granath F et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumour necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 60:3180–3189PubMedCrossRef

AWMF online. Das Portal der wissenschaftlichen Medizin. http://www.awmf.org/leitlinien/detail/anmeldung/1/ll/060–004.html

Bakker MF, Jacobs JW, Welsing PM et al (2011) Low-dose prednisone inclusion into a MTX-based tight control strategy for early rheumatoid arthritis: better control of disease and erosive joint damage. Results from the double-blind randomized CAMERA-II trial. Ann Rheum Dis 70(Suppl3):114CrossRef

Bakker MF, Jacobs JW, Welsing PM et al (2011) Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 70:1099–1103PubMedCrossRef

Barnabe C, Martin BJ, Ghali WA (2011) Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 63:522–529CrossRef

Bathon J, Robles M, Ximenes AC (2011) Sustained disease remission and inhibition of radiographic progression in methotrexate-naïve patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 70:1949–1956PubMedCrossRef

Benedict A, Vanness DJ, Roy S, Cifaldi MA (2010) Comparative effectiveness of biologic therapies for treating rheumatoid arthritis (RA) in patients who failed an anti–tumor necrosis factor agent: a meta-regression analysis. Arthritis Rheum 62(Suppl 10):2266

Bergman GJ, Hochberg MC, Boers M et al (2010) Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39:425–441PubMedCrossRef

Bird, Paul, Griffiths, Hedley et al (2010) The Optimising Patient Outcomes in Australian RheumatoLogy [OPAL] Consortium, multi-centre, cross-sectional, observational study of the safety of methotrexate and leflunomide in combination in the treatment of patients with rheumatoid arthritis the SMILE Study. Safety of methotrexate in combination with leflunomide. Arthritis Rheum 62(Suppl10):319

10.

Breedveld F, Keystone E, Heijde D van der et al (2011) Initial combination therapy with adalimumab plus methotrexate leads to better long-term outcomes in patients with early rheumatoid arthritis: 8-year results of the premier trial. Ann Rheum Dis 70(Suppl 3):254CrossRef

11.

Buttgereit F, Doering G, Schaeffler A et al (2010) Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 69:1275–1280PubMedCrossRef

12.

Chatzidionysiou K, Lie E, Nasonov E et al (2012) Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 71:374–377PubMedCrossRef

13.

Chatzidionysiou K, Lie E, Nasonov E et al (2011) Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 70:1575–1580PubMedCrossRef

14.

Curtis JR, Xie F, Chen L et al (2011) The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 70:1401–1406PubMedCrossRef

15.

Devine EB, Alfonso-Cristancho R, Sullivan SD (2011) Effectiveness of biologic therapies for rheumatoid arthritis: an indireact comparisons approach. Pharmacotherapy 31:39–51PubMedCrossRef

16.

Dirven L, Broek M van den, Klarenbeek NB et al (2011) Clinical and radiological outcomes of four DAS driven treatment strategies: 7-year results of the BeSt study. Ann Rheum Dis 70(Suppl 3):642CrossRef

17.

Dixon WG, Suissa S, Hudson M (2011) The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Ann Rheum Dis 70(Suppl 3):599CrossRef

18.

Dougados M, Huizinga T, Sheeran T et al (2011) Tocilizumab plus methotrexate does not have superior clinical efficacy to TCZ alone in RA patients with inadequate response to MTX: 24-week results oft the ACT-RAY study. Ann Rheum Dis 70(Suppl 3):73

19.

Dreyer L, Mellemkjær L, Hetland ML (2011) No increased cancer risk in patients with rheumatoid arthritis, psoriatic arthritis or other arthritides treated with anti-tumour necrosis factor agents – a long-term follow-up study from the nationwide Danish DANBIO registry. Ann Rheum Dis 70(Suppl 3):410

20.

Emery P, Fleischmann R, Heijde D van der et al (2011) The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 63:1200–1210PubMedCrossRef

21.

Emery P, Breedveld F, Heijde D van der et al (2010) Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 62:674–682PubMedCrossRef

22.

Fedorenko E, Lukina GV, Sigidin YA et al (2011) Remission as the main goal of treatment in early rheumatoid arthritis (RA) patients: comparative efficacy of four treatment regimens. Ann Rheum Dis 70(Suppl 3):598

23.

Finckh A, Dehler S, Gabay C et al (2009) The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 68:33–39PubMedCrossRef

24.

Finckh A, Ciurea A, Brulhart L et al (2010) Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 69:387–393PubMedCrossRef

25.

Gaujoux-Viala C, Smolen JS, Landewe R et al (2010) Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:1004–1009PubMedCrossRef

26.

Gómez-Reino J-J, Sanmartí R, Romero A-B, Monclus L (2010) Rituximab vs TNF-inhibitor cycling in patients Who previously failed to TNF-inhibitors: the MIRAR Study. Arthritis Rheum 62(Suppl 10):409CrossRef

27.

Gorter SL, Bijlsma JW, Cutolo M et al (2010) Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:1010–1014PubMedCrossRef

28.

Graudal N, Jürgens G (2010) Similar effects of disease-modifying antirheuamtic drugs, glucocorticoids and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 62:2852–2853PubMedCrossRef

29.

Greenberg JD, Kremer JM, Curtis JR et al (2011) Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 70:576–582PubMedCrossRef

30.

Greenberg JD, Reed G, Kremer JM et al (2010) Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 69:380–386PubMedCrossRef

31.

Hafstrem I, Albertsson K, Boonen A et al (2009) Remission achieved after 2 years treatment with low-dose prednisolone in addition to diseasemodifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis 68:508–513CrossRef

32.

Hetland ML, Stengaard-Pedersen K, Junker P et al (2010) Radiographic progression and remission rates in early rheumatoid arthritis: MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomized CIMESTRA trial. Ann Rheum Dis 69:789–795CrossRef

33.

Katchamart W, Trudeau J, Phumethum V, Bombardier C (2010) Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying antirheumatic drugs for rheumatoid arthritis. Cochrane database Syst Rev 4 ppCD008495

34.

Kekow J, Müller-Ladner U, Schulze-Koops H et al (2010) Real life treatment with rituximab in TNF blocker non-responders is superior to treatment with a second TNF blocker. Arthritis Rheum 62(Suppl 10):406

35.

Klarenbeek NB, Güler-Yüksel M, Kooij SM van der et al (2011) The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 70:1039–1046PubMedCrossRef

36.

Knevel R, Schoels M, Huizinga TWJ et al (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:987–994PubMedCrossRef

37.

Komano Y, Tanaka M, Nanki T et al (2011) Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 38:1258–1264PubMedCrossRef

38.

Kremer J, Ritchlin C, Mendelsohn A et al (2010) Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 62:917–928PubMedCrossRef

39.

Kristensen LE, Jakobsen AK, Bartels EM et al (2011) The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scand J Rheumatol 40:1–7PubMedCrossRef

40.

Kuriya B, Arkema EV, Bykerk VP, Keystone EC (2010) Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 69:1298–1304PubMedCrossRef

41.

Le Blay P, Mouterde G, Barnetche T, Combe B (2010) Risk of malignancy during Anti-TNF alfa therapy in patients with rheumatoid arthritis: systematic review and meta-analysis of registries, long-term extension studies and randomized controlled trials. Arthritis Rheum 62(Suppl 10):408CrossRef

42.

Liberati A, Douglas G, Altman D et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65–W94PubMed

43.

Lie E, Heijde D van der, Uhlig T et al (2011) Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register. Ann Rheum Dis 70:2103–2110PubMedCrossRef

44.

Lunt M, Watson KD, Dixon WG et al (2010) No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 62:3145–3153PubMedCrossRef

45.

Ma MH, Kingsley GH, Scott DL (2010) A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology 49:91–98PubMedCrossRef

46.

Machold KP, Landewe R, Smolen JS et al (2010) The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomized, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis 69:495–502PubMedCrossRef

47.

Mariette X, Matucci-Cerinic M, Pavelka K et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904PubMedCrossRef

48.

Maxwell LJ, Singh JA (2010) Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheum 37:234–245PubMedCrossRef

49.

Mercer LK, Davies R, Lunt M et al (2011) Risk of cancer in patients receiving non-biologic disease modifying therapy for rheumatoid arthritis: results from the BSR biologics register (BSRBR). Ann Rheum Dis 70(Suppl 3):456

50.

Müller-Ladner U (2009) Unifying abbreviations for biologics in rheumatology-does the idea hold promise? Rheumatology 48:704PubMedCrossRef

51.

Nam JL, Winthrop KL, Vollenhoven RF van et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69:976–986PubMedCrossRef

52.

Nam JL, Villeneuve E, Conaghan PG et al (2011) A preliminary report of remission induction with two therapeutic strategies with infliximab or high dose intervenous steroids for the treatment of rheumatoid arthritis. Ann Rheum Dis 70(Suppl 3):121

53.

Navarro-Sarrabia F, Ruiz-Montesinos D, Hernandez B et al (2009) DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. BMJ Muskuloskelet Disord 10:91CrossRef

54.

Nishimoto N, Miyasaka N, Yamamoto K et al (2009) Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 9:12–19CrossRef

55.

OCEBM Levels of Evidence Working Group*. „The Oxford 2011 Levels of Evidence“. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o = 5653

56.

Rantalaiho V, Korpela M, Hannonen P et al (2009) The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 60:1222–1231PubMedCrossRef

57.

Rigby W, Ferraccioli G, Greenwald M et al (2011) Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res 63:711–720CrossRef

58.

Ruiz Garcia V, Jobanputra P, Burls A et al (2011) Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 16:CD007649

59.

Salliot C, Finckh A, Katchamart W et al (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis Ann Rheum Dis 70:266–271

60.

Salmon-Ceron D, Tubach F, Lortholary O et al (2011) Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 70:616–623PubMedCrossRef

61.

Schiff M, Beaulieu A, Scott DL, Rashford M (2010) Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials. Clin Drug Investig 30:613–624PubMedCrossRef

62.

Schoels M, Wong JB, Aletaha D, Smolen JS (2010) Comparative effectiveness of biological treatment options following tumor necrosis factor inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Arthritis Rheum 62(Suppl 10):1795

63.

Sibilia J, Graninger W, Östör A et al (2011) Comparison of tocilizumab as monotherapy or with add-on DMARDs in patients with rheumatoid arthritis and an inadequate response to previous treatments: ACT-SURE results. Ann Rheum Dis 70(Suppl 3):466

64.

Singh JA, Noorbaloochi S, Singh G (2010) Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 20:CD008341

65.

Singh JA, Christensen R, Wells GA (2009) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 4 John Wiley & Sons, Ltd, Chichester. doi: 10.1002/14651858.CD007848

66.

Singh JA, Beg S, Lopez-Olivo MA (2010) Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev 7 John Wiley & Sons, Ltd, Chichester. doi: 10.1002/14651858.CD008331

67.

Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975PubMedCrossRef

68.

Smolen JS, Han C, Van Der Heijde D et al (2009) Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 68(6):823–827PubMedCrossRef

69.

Smolen JS, Emery, Ferraccioli GF et al (2011) Efficacy and safety of certolizumab pegol after incomplete response to DMARDs in RA patients with low moderate disease activity: results from CERTAIN, a phase IIIb study. Ann Rheum Dis 70(Suppl 3):259CrossRef

70.

Smolen JS, Fleischmann R, Emery P et al (2011) The OPTIMA study of methotrexate and adalimumab: 78-week outcomes in early rheumatoid arthritis patients based on achieving a low DAS28 target after 26 weeks. Ann Rheum Dis 70(Suppl 3):259CrossRef

71.

Soliman MM, Ashcroft DM, Watson KD et al (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:583–589PubMedCrossRef

72.

Soubrier M, Lukas C, Sibilia J et al (2011) Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 70:611–615PubMedCrossRef

73.

Soubrier M, Puéchal X, Sibilia J et al (2009) Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 48:1429–1434PubMedCrossRef

74.

Strangfeld A, Hierse F, Kekow J et al (2009) Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68:1856–1862PubMedCrossRef

75.

Strangfeld A, Hierse F, Rau R et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5PubMedCrossRef

76.

Tak PP, Rigby WF, Rubbert-Roth A et al (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70:39–46PubMedCrossRef

77.

Tanaka Y, Harigai M, Takeuchi T et al (2011) Golimumab, a human anti-TNFα monoclonal antibody administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy: 24-week results of clinical and radiographic assessments. Ann Rheum Dis 70(Suppl 3):422

78.

Todoerti M, Scire CA, Boffini N et al (2010) Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann NY Acad Sci 1193:139–145PubMedCrossRef

79.

Van Dartel S, Fransen J, Kievit W et al (2011) The difference between adalimumab, infliximab and etanercept on the risk of serious infections in patients with rheumatoid arthritis: results from the DREAM registry. Ann Rheum Dis 70(Suppl 3):417

80.

Van Tuyl LHD, Boers M, Lems WF et al (2010) Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 69:807–812CrossRef

81.

Vollenhoven RF van, Ernestam S, Geborek P et al (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374 459–466

82.

Vermeer M, Kuper, IH, Hoekstra M et al (2010) Long-term remission in daily clinical practice: excellent 2 year results with treatment to target in very early rheumatoid arthritis, results of the DREAM remission induction cohort. Arthritis Rheum 62(Suppl 10):662

83.

Verstappen SM, McCoy MJ, Roberts C et al (2010) Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis 69:503–509PubMedCrossRef

84.

Volkmann ER, Agrawal H, Maranian P, Furst DE (2010) Rituximab for rheumatoid arthritis: a meta-analysis and systematic review. Clin Med Insights 2:749–760

Titel: Systematische Literaturrecherche für die S1-Leitlinie zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis
verfasst von: Dr. K. Albrecht
K. Krüger
U. Müller-Ladner
J. Wollenhaupt
Publikationsdatum: 01.09.2012
Verlag: Springer-Verlag
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe 7/2012
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-012-1048-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Zusammenfassung

Hintergrund

Methodik

Ergebnisse

Schlussfolgerungen

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2012

Neurologie und Rheumatologie

Biologika bei Kindern und Jugendlichen zur Behandlung rheumatischer Erkrankungen

Mitteilungen

Mesenchymale Stammzellen und Rheuma

Neurologische Manifestationen bei Kollagenosen